You are here

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of HIV Type 1 Viral Suppression:

TitleDual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of HIV Type 1 Viral Suppression:
Publication TypeJournal Article
Year of Publication2017
AuthorsPulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR
Corporate AuthorsDUAL-GESIDA-8014-RIS-EST45 Study Group
JournalClin Infect Dis
Volume65
Issue12
Pagination2112-2118
Date Published2017 Nov 29
ISSN1537-6591
KeywordsAdult, Anti-HIV Agents, CD4 Lymphocyte Count, Darunavir, Dideoxynucleosides, Emtricitabine, Female, HIV Infections, HIV Protease Inhibitors, HIV-1, Humans, Lamivudine, Male, Medication Therapy Management, Middle Aged, Ritonavir, RNA, Viral, Tenofovir, Viral Load
Abstract

Background: Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression.

Methods: This was a multicenter, open-label, noninferiority trial (margin 12%). Patients with HIV-1 RNA

Results: A total of 249 participants received study drugs (intention-to-treat exposed). The proportion of participants with HIV-RNA

Conclusions: Dual therapy with darunavir/ritonavir and lamivudine demonstrated noninferior therapeutic efficacy and similar tolerability compared to triple therapy.

Clinical Trials Registration: NCT02159599.

DOI10.1093/cid/cix734
Alternate JournalClin. Infect. Dis.
PubMed ID29020293